Scientists hunt for clues to predict immunotherapy success in endometrial cancer
NCT ID NCT07374809
First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This study aims to find biological markers that can predict which patients with advanced or recurrent endometrial cancer will benefit from immunotherapy. Researchers will analyze tumor samples from 50 women to study genetic, epigenetic, and other features. The goal is to personalize treatment and improve outcomes for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DMMR CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Europeo di Oncologa
Milan, Lombardy, 20141, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.